Reimagining Diabetes: From Molecular Mechanisms to Transformative Therapies (A3)
January 31-February 4, 2027 | Keystone Resort, Keystone, CO, United States
Anna Krook, Jennifer Green and David Moller
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
| 4:00–5:00 PM |
Welcome and Keynote Address |
|
| |
Daniel J. Drucker, Lunenfeld-Tanenbaum Research Institute
The Expanding Benefits of GLP-1 Medicines-is Weight Loss Always Critical |
|
| 5:00–7:00 PM |
Fine Tuning our Understanding of Genetic Causes for Metabolic Disease |
|
| |
Ruth J Loos, University of Copenhagen
Identification of Genes and Genetic Loci Contributing to the Risk of Obesity and Related Traits |
|
| |
Melina Claussnitzer, Broad Institute, Harvard Medical School and Massachusetts General Hospital
Moving from Variant to Function to Tractable Therapeutic Hypotheses |
|
| |
Bart O. Roep, Leiden University Medical Center
Genetic beta-Cell Protection Modulating Type 1 Diabetes |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
Tuesday, February 2, 2027
| 8:00–11:00 AM |
New Mechanisms with Clinical Results |
|
| |
David Moller, Third Rock Ventures
Overview of Emerging Clinical Trial Results - Impact and Implications |
|
| |
David Kendall †, Zealand Pharma
Amylin Biology-Rationale and Clinical Results |
|
| |
Scott Harris, Altimmune Inc.
Harnessing Glucagon Agonism to Amplify Efficacy |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion 1: Lessons from Diabetes-Obesity Clinical Trials |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Breakthrough Opportunities for Type 1 Diabetes and Preservation of Pancreatic B-Cell Mass-Function |
|
| |
Matthias Hebrok, Technical University Munich and Helmholtz Center Munich
Advances toward Realizing the Goal of Stem Cell-Derived Islet Replacement Therapies |
|
| |
Pedro Herrera †, University of Geneva
Regenerative Medicine, Islet Health, and Disease-Modifying Approaches |
|
| |
Kevan C. Herold, Yale University
Clinical Trial Advances to Decode Beta Cell Resilience in Type 1 Diabetes: Cellular Pathways that Prevent Immune Destruction |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, February 3, 2027
| 8:00–11:00 AM |
Disease Biology and Novel Therapeutic Targets |
|
| |
Anna Krook, Karolinska Institutet
Skeletal Muscle as a Player in Pathobiology and a Therapeutic Target Organ |
|
| |
Mitchell A. Lazar †, Perelman School of Medicine, University of Pennsylvania
Role of Adipose Tissue and Transcriptional Control of Metabolism |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion 2: Global Perspectives in Diabetes Drug Development and Access to Care |
|
| 12:00–1:00 PM |
Poster Setup |
|
| 12:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Addressing Shortcomings and Expanding Use of Incretin-Based Therapies |
|
| |
Philip Larsen, Sixpeaks Bio AG
Residual Challenges: Weight Regain, Sarcopenia, Long-Term Weight Maintenance |
|
| |
Rotonya Carr, University of Washington
Treating Metabolic Dysfunction-Associated Steatotic Liver Disease |
|
| |
Brian Finan, Eli Lilly
Incretin based Tri Agonists |
|
| |
Lotte Bjerre Knudsen, Novo Nordisk A/S
GLP-1 and Beyond: Clinical Drug-Specific Mechanisms in Diabetes, Obesity, Cardiovascular, Kidney, Liver and Brain Diseases |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Thursday, February 4, 2027
| 8:00–11:00 AM |
New Approaches Aimed at Modulating Energy Balance |
|
| |
Randy J. Seeley, University of Michigan
Neural Pathways Regulating Food Intake and Energy Balance |
|
| |
Katrin J. Svensson, Stanford University
Novel Peptides that Regulate Feeding and Obesity |
|
| |
Eleftheria Maratos-Flier †, Harvard Medical School and Alnylam
FGF21: What have we Learned from Mice and Human Trials? |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 12:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:30 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Clinical Technology Innovations & Devices |
|
| |
Emmanuel Opara, Wake Forest Institute for Regenerative Medicine
Re-Engineering the Bioartificial Pancreas |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:15 PM |
Panel Discussion 3: What Does the Future Hold for Strategies to Predict, Prevent, and Treat Diabetes Mellitus |
|
| |
* Jennifer Green, Duke University
|
|
| 7:15–7:30 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
|
| 7:30–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
